上海醫藥(02607.HK)下屬控股子公司腦血栓藥物注射用尤瑞克林新納入國家醫保目錄
格隆匯11月29日丨上海醫藥(02607.HK)公佈,根據國家醫療保障局網站於2019年11月28日發佈的《關於將2019年談判藥品納入
<國家基本醫療保險、工傷保險和生育保險藥品目錄>
乙類範圍的通知》(醫保發【2019】65號),公司屬控股子公司廣東天普生化醫藥股份有限公司(以下簡稱"上藥天普")的獨家產品注射用尤瑞克林(商品名"凱力康")通過了醫保談判,首次被納入《國家基本醫療保險、工傷保險和生育保險藥品目錄(2019年版)》(以下簡稱"《醫保目錄》")。
國家基本醫療保險、工傷保險和生育保險藥品目錄>
經統計,公司共有643個品種納入本次《醫保目錄》,其中60個重點品種中已納入《醫保目錄》的共計46個。
注射用尤瑞克林為上藥天普獨家生產的國家一類新藥,2005年上市,先後被國家科技部列為"1035"工程、火炬計劃、國家"十五"重大科技項目。該藥通過獨特的激肽釋放酶-激肽系統,靶向開啟腦缺血區側支循環,快速改善腦血流灌注,適用於輕-中度急性血栓性腦梗死。目前,注射用尤瑞克林被我國五部權威腦卒中診療指南、一部指導規範、一部共識和兩部教科書推薦,是臨牀不可或缺的一線治療用藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.